1CLD.F
California Resources Corporation
FrankfurtEUREQUITY
Energy
DELAYED
Last price
45.79
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
45.79
Day high
46.03
Day low
44.91
Volume
89
Market cap
$4.07B
P/E (TTM)
—
52W range
36.60 – 62.00
Trailing performance
Returnvs SPY
1W
-0.63%
+0.7%
1M
-3.62%
-7.4%
3M
-12.88%
-16.0%
6M
-6.55%
-17.6%
YTD
+23.76%
+11.5%
1Y
+8.00%
-12.0%
3Y
-10.22%
-84.4%
5Y
+37.10%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on 1CLD.F open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
4.40M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 10, 26 | BYS JAY A Officer |
SELL | 11.91K | $642.98K | Direct |
| Jul 13, 26 | BYS JAY A Officer |
SELL | 11.91K | $642.98K | Direct |
| Jun 18, 26 | HAYAT OMAR Chief Operating Officer |
STOCK | 7.31K | $0 | Direct |
| Jun 4, 26 | BYS JAY A Officer |
SELL | 11.91K | $734.42K | Direct |
| May 12, 26 | PRESTON MICHAEL L. General Counsel |
SELL | 26.41K | $1.58M | Direct |
| May 8, 26 | HAYAT OMAR Chief Operating Officer |
STOCK | 173 | $0 | Direct |
| Apr 30, 26 | ROBY WILLIAM B Director |
STOCK | 3.09K | $0 | Direct |
| Apr 30, 26 | BREMNER ANDREW B Director |
STOCK | 3.09K | $0 | Direct |
| Apr 30, 26 | CHAPMAN JAMES N Director |
STOCK | 3.09K | $0 | Direct |
| Apr 30, 26 | CEPAK TIFFANY THOM Director |
STOCK | 5.02K | $0 | Direct |
| Apr 30, 26 | VELTMANN ALEJANDRA Director |
STOCK | 3.09K | $0 | Direct |
| Apr 30, 26 | KENDALL CHRISTIAN S Director |
STOCK | 3.09K | $0 | Direct |
| Apr 30, 26 | MCFARLAND MARK ALLEN Director |
STOCK | 3.09K | $0 | Direct |
| Mar 12, 26 | CANADA PENSION PLAN INVESTMENT BOARD Beneficial Owner of more than 10% of a Class of Security |
SELL | 3.50M | $213.85M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BYS JAY A |
Officer | 159.42K | Sale |
CANADA PENSION PLAN INVESTMENT BOARD |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
CEPAK TIFFANY THOM |
Director | 86.33K | Stock Award(Grant) |
CRESPY CLIO C |
Chief Financial Officer | 98.50K | Stock Award(Grant) |
GOULD CHRISTOPHER D |
Officer | 131.54K | Sale |
HAYAT OMAR |
Chief Operating Officer | 83.49K | Stock Award(Grant) |
LEON FRANCISCO |
Chief Executive Officer | 336.95K | Stock Award(Grant) |
MCFARLAND MARK ALLEN |
Director | 79.36K | Stock Award(Grant) |
PRESTON MICHAEL L. |
General Counsel | 104.21K | Sale |
ROBY WILLIAM B |
Director | 60.27K | Stock Award(Grant) |
Fundamentals
Market cap$4.07B
Enterprise value$5.36B
Revenue (TTM)$3.74B
Gross profit$2.12B
EBITDA$600.00M
Net income$-121.00M
EPS (TTM)$-1.07
Free cash flow$335.12M
Total cash$56.00M
Total debt$1.35B
Book value / share$32.77
Shares outstanding88.82M
Float83.22M
Short % of float—
Dividend yield3.06%
Beta (5Y)0.90
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio0.26
Price / sales—
Price / book1.40
EV / revenue1.44
EV / EBITDA8.93
Gross margin56.76%
Operating margin46.79%
Profit margin-3.24%
Return on equity-3.55%
Return on assets0.76%
Debt / equity39.59
Current ratio0.66
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $3.40B | $2.96B | $2.81B | $3.23B | +15.1% |
| Operating revenue | $3.38B | $2.93B | $2.77B | $3.23B | +15.4% |
| Cost of revenue | $1.95B | $1.55B | $1.27B | $1.27B | +25.7% |
| Gross profit | $1.46B | $1.41B | $1.54B | $1.97B | +3.4% |
| Selling, general & admin | $333.00M | $321.00M | $267.00M | $222.00M | +3.7% |
| Total operating expense | $1.02B | $998.00M | $743.00M | $684.00M | +1.8% |
| Operating income | $442.00M | $412.00M | $799.00M | $1.28B | +7.3% |
| Net interest income | -$106.00M | -$87.00M | -$56.00M | -$30.00M | -21.8% |
| Pre-tax income | $502.00M | $516.00M | $748.00M | $761.00M | -2.7% |
| Tax provision | $139.00M | $140.00M | $184.00M | $237.00M | -0.7% |
| Net income | $363.00M | $376.00M | $564.00M | $524.00M | -3.5% |
| Net income to common | $363.00M | $376.00M | $564.00M | $524.00M | -3.5% |
| Basic EPS | 4.17 | 4.74 | 8.10 | 6.94 | -12.0% |
| Diluted EPS | 4.15 | 4.62 | 7.78 | 6.75 | -10.2% |
| EBIT | $608.00M | $603.00M | $804.00M | $814.00M | +0.8% |
| EBITDA | $1.12B | $991.00M | $1.03B | $1.01B | +12.9% |
| Basic shares | 87.00M | 79.30M | 69.60M | 75.50M | +9.7% |
| Diluted shares | 87.40M | 81.40M | 72.50M | 77.60M | +7.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $132.00M | $372.00M | $496.00M | $307.00M | -64.5% |
| Cash & short-term investments | $132.00M | $372.00M | $496.00M | $307.00M | -64.5% |
| Accounts receivable | $333.00M | $330.00M | $216.00M | $326.00M | +0.9% |
| Inventory | $106.00M | $90.00M | $72.00M | $60.00M | +17.8% |
| Total current assets | $938.00M | $1.02B | $929.00M | $864.00M | -8.4% |
| Property, plant & equipment | $5.99B | $5.79B | $2.84B | $2.86B | +3.5% |
| Total assets | $7.40B | $7.13B | $4.00B | $3.97B | +3.8% |
| Total current liabilities | $1.05B | $980.00M | $616.00M | $894.00M | +7.1% |
| Long-term debt | $1.28B | $1.13B | $540.00M | $592.00M | +13.3% |
| Total debt | $1.36B | $1.22B | $610.00M | $662.00M | +11.1% |
| Total liabilities | $3.73B | $3.60B | $1.78B | $2.10B | +3.7% |
| Retained earnings | $1.91B | $1.68B | $1.42B | $938.00M | +13.4% |
| Shareholder equity | $3.67B | $3.54B | $2.22B | $1.86B | +3.8% |
| Working capital | -$112.00M | $44.00M | $313.00M | -$30.00M | -354.5% |
| Net tangible assets | $3.67B | $3.54B | $2.22B | $1.86B | +3.8% |
| Shares issued | 110.65M | 109.61M | 83.56M | 83.41M | +0.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $363.00M | $376.00M | $564.00M | $524.00M | — | -3.5% |
| Change in working capital | -$141.00M | -$97.00M | $6.00M | -$57.00M | — | -45.4% |
| Operating cash flow | $865.00M | $610.00M | $653.00M | $690.00M | — | +41.8% |
| Capital expenditure | — | — | -$185.00M | -$12.00M | -$194.00M | — |
| Investing cash flow | -$725.00M | -$1.08B | -$175.00M | -$317.00M | — | +32.7% |
| Share buybacks | -$389.00M | -$234.00M | -$146.00M | -$313.00M | — | -66.2% |
| Dividends paid | -$136.00M | -$113.00M | -$81.00M | -$59.00M | — | -20.4% |
| Financing cash flow | -$380.00M | $343.00M | -$289.00M | -$371.00M | — | -210.8% |
| Free cash flow | $865.00M | $610.00M | $653.00M | $690.00M | — | +41.8% |
| End cash position | $132.00M | $372.00M | $496.00M | $307.00M | — | -64.5% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $967.00M | $798.00M | $878.00M | $816.00M | $906.00M | — | +21.2% |
| Operating revenue | $957.00M | $791.00M | $874.00M | $816.00M | $900.00M | — | +21.0% |
| Cost of revenue | $521.00M | $501.00M | $483.00M | $464.00M | $497.00M | — | +4.0% |
| Gross profit | $446.00M | $297.00M | $395.00M | $352.00M | $409.00M | — | +50.2% |
| Selling, general & admin | $106.00M | $95.00M | $87.00M | $79.00M | $72.00M | — | +11.6% |
| Total operating expense | $285.00M | $293.00M | $244.00M | $244.00M | $235.00M | — | -2.7% |
| Operating income | $161.00M | $4.00M | $151.00M | $108.00M | $174.00M | — | +3,925.0% |
| Net interest income | -$29.00M | -$29.00M | -$25.00M | -$20.00M | -$27.00M | — | 0.0% |
| Pre-tax income | -$760.00M | $23.00M | $75.00M | $242.00M | $162.00M | — | -3,404.3% |
| Tax provision | -$49.00M | $11.00M | $11.00M | $70.00M | $47.00M | — | -545.5% |
| Net income | -$711.00M | $12.00M | $64.00M | $172.00M | $115.00M | — | -6,025.0% |
| Net income to common | -$711.00M | $12.00M | $64.00M | $172.00M | $115.00M | — | -6,025.0% |
| Basic EPS | -8.02 | 0.14 | — | 1.93 | 1.27 | 0.36 | -5,828.6% |
| Diluted EPS | -8.02 | 0.14 | — | 1.92 | 1.26 | 0.36 | -5,828.6% |
| EBIT | -$731.00M | $52.00M | $100.00M | $267.00M | $189.00M | — | -1,505.8% |
| EBITDA | -$598.00M | $181.00M | $223.00M | $395.00M | $320.00M | — | -430.4% |
| Basic shares | 88.70M | 84.60M | — | 89.00M | 90.60M | 90.80M | +4.8% |
| Diluted shares | 88.70M | 85.10M | — | 89.40M | 91.20M | 92.20M | +4.2% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $40.00M | $132.00M | $196.00M | $72.00M | $214.00M | -69.7% |
| Cash & short-term investments | $40.00M | $132.00M | $196.00M | $72.00M | $214.00M | -69.7% |
| Accounts receivable | $454.00M | $333.00M | $286.00M | $297.00M | $308.00M | +36.3% |
| Inventory | $107.00M | $106.00M | $94.00M | $93.00M | $91.00M | +0.9% |
| Total current assets | $788.00M | $938.00M | $812.00M | $728.00M | $799.00M | -16.0% |
| Property, plant & equipment | $5.98B | $5.99B | $5.63B | $5.65B | $5.72B | -0.1% |
| Total assets | $7.15B | $7.40B | $6.75B | $6.71B | $6.83B | -3.4% |
| Total current liabilities | $1.44B | $1.05B | $917.00M | $928.00M | $961.00M | +37.2% |
| Current debt | — | — | $122.00M | $122.00M | $122.00M | — |
| Long-term debt | $1.31B | $1.28B | $889.00M | $888.00M | $888.00M | +2.1% |
| Total debt | $1.38B | $1.36B | $1.10B | $1.09B | $1.10B | +1.4% |
| Total liabilities | $4.23B | $3.73B | $3.31B | $3.31B | $3.31B | +13.5% |
| Retained earnings | $1.16B | $1.91B | $1.93B | $1.90B | $1.76B | -39.2% |
| Shareholder equity | $2.92B | $3.67B | $3.44B | $3.41B | $3.52B | -20.6% |
| Working capital | -$653.00M | -$112.00M | -$105.00M | -$200.00M | -$162.00M | -483.0% |
| Net tangible assets | $2.92B | $3.67B | $3.44B | $3.41B | $3.52B | -20.6% |
| Shares issued | 110.91M | 110.65M | 105.06M | 105.03M | 109.96M | +0.2% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$711.00M | $12.00M | $64.00M | $172.00M | $115.00M | -6,025.0% |
| Change in working capital | -$148.00M | $24.00M | -$43.00M | -$56.00M | -$66.00M | -716.7% |
| Operating cash flow | $99.00M | $235.00M | $279.00M | $165.00M | $186.00M | -57.9% |
| Investing cash flow | -$136.00M | -$508.00M | -$87.00M | -$51.00M | -$79.00M | +73.2% |
| Share buybacks | -$22.00M | -$25.00M | -$35.00M | -$221.00M | -$112.00M | +12.0% |
| Dividends paid | -$38.00M | -$33.00M | -$32.00M | -$35.00M | -$36.00M | -15.2% |
| Financing cash flow | -$55.00M | $209.00M | -$68.00M | -$256.00M | -$265.00M | -126.3% |
| Free cash flow | $99.00M | $235.00M | $279.00M | $165.00M | $186.00M | -57.9% |
| End cash position | $40.00M | $132.00M | $196.00M | $72.00M | $214.00M | -69.7% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $986.13M | +15.3% |
| Next quarter | — | — | $963.30M | +4.3% |
| Current year | — | — | $3.45B | -5.9% |
| Next year | — | — | $3.64B | +5.5% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders4.95%
Held by institutions105.81%
Institutions holding509
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
46.07
-0.61% from price
SMA 20
45.39
+0.88% from price
SMA 50
46.02
-0.51% from price
SMA 100
49.91
-8.25% from price
SMA 200
47.47
-3.54% from price
EMA 12
45.78
+0.02% from price
EMA 26
45.88
-0.20% from price
EMA 50
46.72
-1.99% from price
RSI (14)
49.3
Neutral
MACD (12,26,9)
-0.10
Hist 0.09
ATR (14)
1.23
2.70% of price
Realised vol 30D
29.1%
Annualised
Bollinger upper
47.19
20, 2σ
Bollinger lower
43.59
20, 2σ
50 / 200 cross
Death
46.02 vs 47.47
Trend bias
Below 200
-3.54%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.34
Less volatile than market
Correlation to SPY
-0.12
Largely independent
Realised vol 30D
29.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-27.3%
Peak to trough
Max drawdown 5Y
-48.4%
Peak to trough
ATR 14
1.23
2.70% of price
Beta (reported)
0.90
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Aug 12, 26 | UBS | MAINTAINED | Buy | Buy |
| Aug 11, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 17, 26 | Stephens & Co. | MAINTAINED | Overweight | Overweight |
| Jul 13, 26 | UBS | MAINTAINED | Buy | Buy |
| Jun 30, 26 | Citigroup | MAINTAINED | Buy | Buy |
| May 27, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| May 26, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| May 20, 26 | Citigroup | UPGRADE | Neutral | Buy |
| May 11, 26 | UBS | MAINTAINED | Buy | Buy |
| Apr 13, 26 | UBS | MAINTAINED | Buy | Buy |
| Mar 30, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate$1.40 / yr
Forward yield3.06%
5-year avg yield—
Payout ratio37.77%
Ex-dividend dateSep 4, 2026
Next pay date—
Last split—
Split date—
Headlines
TME Pharma provides update on its activities
GlobeNewswire · 10m ago
American Chemical Society Names Syngenta's Camilla Corsi the 2026 Winner of Prestigious International Award for Research in Agrochemicals
Business Wire · 15m ago
Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
Business Wire · 15m ago
Board Update
GlobeNewswire · 15m ago
Aegon implements EUR 150 million increase in share buyback program
GlobeNewswire · 15m ago
TOMY's "TOMICA XROSS RESCUE" Diorama-based Short Animation Series to Begin Streaming Aug. 26, 2026
PR Newswire · 15m ago
Holding(s) in Company
GlobeNewswire · 15m ago
Summary of AB KN Energies webinar
GlobeNewswire · 15m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.